[1]
Iulita MF, Ower A, Barone C, et al. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: relation to cognitive decline and longitudinal evaluation. Alzheimers Dement 2016; 12(11): 1132-48.
[2]
Iulita MF, Caraci F, Cuello CA. A link between NGF metabolic deregulation and Aβ-driven inflammation in Down syndrome. CNS Neurol Disord Drug Targets 2016; 15(4): 434-47.
[3]
Caraci F, Gulisano W, Guida AC, et al. A key role for TGF-β1 in hippocampal synaptic plasticity and memory. Sci Rep 2015; 5: 11252.
[4]
Caraci F, Castellano S, Salomone S, Drago F, Bosco P, Di Nuovo S. Searching for Disease-Modifying Drugs in AD: can we combine neuropsychological tools with biological markers? CNS Neurol Disord Drug Targets 2014; 13(1): 173-86.
[5]
Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014; 9(5)e96905
[6]
Caraci F, Bosco P, Signorelli M, et al. The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer’s disease and is associated with AD-related depression. Eur Neuropsychopharmacol 2012; 22(2): 281-9.
[7]
Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer’s disease: focus on disease-modifying drugs. Br J Clin Pharmacol 2011; 73(4): 504-17.
[8]
Caraci F, Molinaro G, Battaglia G, et al. Nicolettiet F. Targeting group-II metabotropic glutamate receptors for the treatment of psychosis associated with Alzheimer’s disease: selective activation of mGlu2 receptors amplifies β-amyloid toxicity in cultured neurons whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol Pharmacol 2011; 79(3): 618-26.
[9]
Caraci F, Battaglia G, Bruno V, et al. TGF-ß1 pathway as a new target for neuroprotection in Alzheimer’s disease. CNS Neurosci Ther 2011; 17(4): 237-49.
[10]
Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26(1): 39-67.
[11]
Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer’s disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 2010; 626(1): 64-71.
[12]
Giuffrida ML, Caraci F, Pignataro B, et al. Beta-amyloid monomers are neuroprotective. J Neurosci 2009; 29(34): 10582-7.
[13]
Caraci F, Battaglia G, Busceti C, et al. TGF-β1 protects against Aβ-neurotoxicity via the phosphatidylinositol-3-kinase pathway. Neurobiol Dis 2008; 30(2): 234-42.
[14]
Scali C, Caraci F, Gianfriddo M, et al. Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis 2006; 24(2): 254-65.
[15]
Caricasole A, Copani A, Caraci F, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer’s brain. J Neurosci 2004; 24(26): 6021-7.
